Alu hypomethylation in ischemic stroke: Associations with selected clinical characteristics
6 affiliations
- 1School of Medicine, Walailak University, Nakhon Si Thammarat, Thailand.
- 2Walailak University Hospital, Walailak University, Nakhon Si Thammarat, Thailand.
- 3Research Center in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat, Thailand.
- 4Center for Excellence in Molecular Genetics of Cancer and Human Diseases, Chulalongkorn University, Bangkok, Thailand.
- 5Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- 6Department of Biochemistry, Yong Loo Lin-School of Medicine, National University of Singapore, Singapore, Singapore.
Abstract
This study investigated Alu methylation levels in 85 ischemic stroke patients and 50 healthy controls, using Alu-Combined Bisulfite Restriction Analysis (COBRA) a quantitative approach to assess methylation. Ischemic stroke patients had significantly lower overall Alu methylation as compared to controls (P < 0.0001). Alu methylation was negatively correlated with age in both the control group (r = −0.6131, P < 0.0001) and the ischemic stroke group (r = −0.2834, P = 0.0086). Moreover, among age-matched ischemic stroke patients, there remained a difference between control and ischemic stroke patients (P = 0.0182). Alu methylation remained associated with ischemic stroke status after adjustment for age and sex (adjusted OR = 0.841, 95% CI = 0.709–0.979, P = 0.0327). Within the ischemic stroke group, disease duration was not significantly correlated with Alu methylation in the unadjusted analysis (r = −0.1594, P = 0.1450). However, after adjustment for age and sex, longer disease duration was associated with lower Alu methylation (β = −0.556, 95% CI = −0.994 to −0.117, P = 0.0137). Alu methylation was lower in patients with a history of multiple stroke events (P = 0.0323) and in those with Fazekas scores of 2–3 (P = 0.0324) in the unadjusted comparisons, but neither association remained statistically significant after adjustment for age and sex (P = 0.0542 and P = 0.0684, respectively). Stroke circulation location was not associated with Alu methylation. These findings support an association between Alu methylation and ischemic stroke status. Longer disease duration was also associated with lower Alu methylation after adjustment for age and sex. However, the cross-sectional design does not establish causality, disease progression, or predictive or prognostic value. Longitudinal studies are needed to determine the clinical relevance of these findings.
Related
- Albumin Quality in Oxidative and Ischemic Stress: Implications for Drug Binding and Clinical Pharmacokinetics
- Clinical, single-cell, and spatial transcriptomic integration identifies an RCD-high inflammatory myeloid program for early neurological deterioration and outcome stratification after acute ischemic stroke
- Clinical and MEFV variant characteristics of pediatric patients with an FMF-compatible phenotype and PFAPA-compatible features in a Palestinian referral cohort: a retrospective study
- Clinical and genetic characteristics of patients with disorders of sex development in a large unselected cohort of China
- Tissue-specific moderate DNA methylation alterations featuring hypomethylation in microRNA regulatory regions associated with advanced carotid atherosclerosis
BibTeX
@article{siriarchawawat2026hypomethylation,
title = {{Alu hypomethylation in ischemic stroke: Associations with selected clinical characteristics}},
author = {Doungkamol Siri-Archawawat and Sirithip Chuaijit and Apiwat Mutirangura and Jerald Tan and Jirapan Thongsroy},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0360371},
url = {https://doi.org/10.1371/journal.pone.0360371},
note = {CC BY},
}
RIS
TY - JOUR
TI - Alu hypomethylation in ischemic stroke: Associations with selected clinical characteristics
AU - Doungkamol Siri-Archawawat
AU - Sirithip Chuaijit
AU - Apiwat Mutirangura
AU - Jerald Tan
AU - Jirapan Thongsroy
PY - 2026
DA - 2026/10/21
JO - PLOS One
DO - 10.1371/journal.pone.0360371
UR - https://doi.org/10.1371/journal.pone.0360371
AB - This study investigated Alu methylation levels in 85 ischemic stroke patients and 50 healthy controls, using Alu-Combined Bisulfite Restriction Analysis (COBRA) a quantitative approach to assess methylation. Ischemic stroke patients had significantly lower overall Alu methylation as compared to controls (P < 0.0001). Alu methylation was negatively correlated with age in both the control group (r = −0.6131, P < 0.0001) and the ischemic stroke group (r = −0.2834, P = 0.0086). Moreover, among age-matched ischemic stroke patients, there remained a difference between control and ischemic stroke patients (P = 0.0182). Alu methylation remained associated with ischemic stroke status after adjustment for age and sex (adjusted OR = 0.841, 95% CI = 0.709–0.979, P = 0.0327). Within the ischemic stroke group, disease duration was not significantly correlated with Alu methylation in the unadjusted analysis (r = −0.1594, P = 0.1450). However, after adjustment for age and sex, longer disease duration was associated with lower Alu methylation (β = −0.556, 95% CI = −0.994 to −0.117, P = 0.0137). Alu methylation was lower in patients with a history of multiple stroke events (P = 0.0323) and in those with Fazekas scores of 2–3 (P = 0.0324) in the unadjusted comparisons, but neither association remained statistically significant after adjustment for age and sex (P = 0.0542 and P = 0.0684, respectively). Stroke circulation location was not associated with Alu methylation. These findings support an association between Alu methylation and ischemic stroke status. Longer disease duration was also associated with lower Alu methylation after adjustment for age and sex. However, the cross-sectional design does not establish causality, disease progression, or predictive or prognostic value. Longitudinal studies are needed to determine the clinical relevance of these findings.
SN - 1932-6203
ER -